Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG5101 in relapsed or refractory B-cell non-Hodgkin lymphoma
NL-OMON60954Phase 2Completed
- Sponsor
- Lakefront Biotherapeutics
- Start
- Apr 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GLPG5101 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 6 more (2 arms), sponsored by Lakefront Biotherapeutics. Primary endpoints: Incidence of adverse events, serious adverse events, and dose-limiting toxicities and Objective response. Started Apr 2022; status: completed.
02
Drugs
GLPG5101
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON60954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60954.